Myriad Genetics vs Novocure
Myriad Genetics is the larger business, with $825m of revenue in fiscal 2025 against $655m for Novocure (1.3 times as much). Novocure grew faster (8.3% against -1.6%). Novocure kept more of each dollar of sales as profit: a net margin of -20.8% against -44.4%.
| Latest fiscal year | Myriad GeneticsMYGN, 2025 | NovocureNVCR, 2025 |
|---|---|---|
| Revenue | $825m | $655m |
| Revenue growth | -1.6% | 8.3% |
| Net income | −$366m | −$136m |
| Operating margin | -47.0% | — |
| Net margin | -44.4% | -20.8% |
| Return on equity | -68.5% | -38.9% |
| Free cash flow | $1.8m | −$75.7m |
| Cash | $150m | $93.5m |
| Total debt | $125m | $195m |
| Debt to equity | 34.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 2,700 | 1,605 |
| Market value | $567m | $1.56bn |
| Price vs our value range | — | — |
| Moat score | 26 (Weak) | 36 (Weak) |
| Insider trades, 12 months | 5 buys, 1 sales | 0 buys, 25 sales |